Physician profile
Michael Basedow
NPI 1114467867
$1,216.83
in general payments reported to CMS, 2019-2025
13 companies · $660 in 2025
The $660 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.02 · 2021: $72.92 · 2022: $69.73 · 2023: $62.21 · 2024: $341 · 2025: $660.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $963 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $963.17 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $731.06 | 2022-2025 | Vraylar |
| Janssen Biotech, INC. | $195.33 | 2025 | Tremfya |
| Lilly USA, LLC | $49.41 | 2021 | |
| Sun Pharmaceutical Industries INC. | $42.83 | 2022-2023 | Ilumya |
| Kowa Pharmaceuticals America, INC. | $34.08 | 2025 | Zoryve |
| Genzyme Corporation | $28.22 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $23.94 | 2022 | |
| Amgen INC. | $23.48 | 2025 | Otezla |
| Astrazeneca Pharmaceuticals Lp | $22.93 | 2020-2021 | |
| Paratek Pharmaceuticals, INC. | $19.44 | 2025 | Nuzyra |
| Currax Pharmaceuticals LLC | $17.38 | 2024 | Contrave |
| Pfizer INC. | $17.13 | 2025 | |
| Mylan Specialty L.P. | $11.60 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Basedow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.